North America Methadone Market

North America Methadone Market Size & Growth (2024 to 2029)

As per the research report, the size of the North America Methadone Market was valued at USD xx Million in 2024 and estimated to be growing at a CAGR of xx%, to reach USD xx Million by 2029 during the forecast period 2024 to 2029.

Methadone is a synthetic narcotic analgesic that belongs to the opioids family of drugs. It's a drug that's used to treat chronic pain. One of the essential elements is that methadone belongs to the opioid analgesic drug class, used to treat pain in patients. Methadone binds to the NMDA ionotropic glutamate receptor and functions via attaching to the -opioid receptor, with the agonism of the opioid receptors being used to treat pain.

Another essential feature is the identification of acute encephalopathy in methadone-intoxicated patients, where brain MRI is functional in detecting methadone-induced encephalopathy. In addition, the rising frequency of chronic illnesses among individuals and the increasing incidence of opioid addiction is driving the market's growth.

The Methadone Market is expected to develop as the number of patients undergoing therapeutic pain management and other chronic diseases rises. According to the National Health Council, nearly 157 million people in the United States will have a chronic illness in 2020, which will increase the usage of methadone since it has an ionotropic glutamate receptor, which will boost the Methadone Market's growth over the forecast period.

The expanding number of persons addicted to heroin and other drugs and their treatment, which includes short-term administration of methadone hydrochloride, all contribute to the methadone market's rapid expansion.

Increased adverse effects such as constipation, nausea, vomiting, and others are expected to hinder the Methadone Market's expansion. Furthermore, the Methadone Market would face challenges because of strict government approval.

This research report on the North America Methadone Market has been segmented and sub-segmented into the following categories.

By Application

• Operation
• Detoxification
• Others

By Mode Of Administration

• Injections
• Oral Medicine

By Country

• U.S
• Canada
• Rest of North America

Geographically, the North American methadone market is predicted to rise steadily over the forecast period, owing to the rising prevalence of pain and the growing need for methadone for maintenance and detoxification therapy. Furthermore, oral administration is predicted to be the most profitable method of administration in the global methadone market because methadone comes in a range of forms and dosages.

The U.S Methadone Market dominated globally, with a 40% share. This is due to the rising prevalence of drug addiction and the increased use of opioid medications. As per the United Nations Office on Drugs and Crime (UNODC) study, more than 47,000 people died in 2017 due to an opioid overdose, increasing demand for methadone, which works as an opioid receptor, and driving the market growth.

However, due to the rising population and increased growth in healthcare, the region is expected to outperform all others by recording the highest CAGR of 2% during the projected period 2023-2028.

Pain management is the highest revenue-generating therapeutic area in the North American methadone industry, followed by maintenance therapy. Unfortunately, the prevalence of agony is increasing, as are the incidences of drug addiction.

The Canada Methadone Market is expected to rise at decent CAGR during the period. Methadone has proven a good alternative to morphine sulfate and other opiate analgesics in Canada because of its long half-life and low-risk value. All of these factors contribute to the growing methadone market.

KEY MARKET PLAYERS

Promising Companies playing a dominant role in the North America Methadone Market profiled in this report are Diskets, Mallinckrodt and Roxane (Boehringer Ingelheim), Macfarlan Smith, VistaPharm, Qinghai Pharm, CentralPharm, Aurolife Pharma LLC.,